NEW YORK, NY--(Marketwire - June 04, 2008) - Delcath Systems, Inc. (NASDAQ: DCTH) announced today that the Albany Medical Center has joined Delcath’s Phase III clinical trial for the treatment of inoperable metastatic melanoma in the liver using the Company’s Percutaneous Hepatic Perfusion (PHP) System for the isolated, high dose delivery of the anti-cancer agent melphalan. Albany Medical Center is the fourth center in this multi-center study.
